

ELC ENHANCING DETECTION: FSM TESTING PLAN

2020 Overarching Jurisdictional SARS-COV-2 Testing Strategy

Jurisdiction:	FSM
Population Size:	110000

1. Describe the overarching testing strategy in your state or jurisdiction.

FSM is fortunate to not have any cases of COVID-19. Robust travel restrictions have been in place since the FSM President declared a state of Emergency in January 31, 2020. Points of entry screening have been in place since February 2020. FSM is planning to repatriate stranded residents in early June 2020. The current testing strategy is to test all persons under investigation (PUI) according to current definitions. Additionally, FSM is testing all hospitalized Severe Acute Respiratory Syndrome cases (flags have been set on FSM Electronic Health Records to alert using to test SARI case for COVID-19). The FSM testing algorithm lists the following categories for persons to be tested by priority:

1. A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath, and non-traumatic anosmia), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset; OR,
2. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset; OR
3. A patient with severe acute respiratory illness (SARI)- fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation; OR
4. A patient showing Influenza-like illness (ILI)- onset of fever of 38 °C and cough within the last 10 days; OR
5. A patient showing loss of smell and taste in the absence of an alternative diagnosis.

FSM has 8 ID NOW devices and 8 Gene Xpert IV analyzers. These analyzers are placed in state health service laboratories. Teams of Public Health personnel have been trained on Infection Prevention and Control and Specimen Collection procedures. These personnel are able to collect specimens from persons at quarantine sites. Additional health personnel have been placed at Community Health Centres (5 Pohnpei, 5 Yap, 3 Chuuk, 3 Kosrae) who are able to collect specimens and have these specimens sent via Health Services courier to nearest testing laboratory. Community Health Centres are connected to FSM Health Network: and can use this network to access test results. Since there are no confirmed cases in FSM, serology testing is not applicable at this time. FSM as well as the Pacific Islands Health Officers Association are monitoring test kit supply, reagent inventory and staffing on a weekly basis. Most updates are provided by scheduled Zoom calls.

ELC ENHANCING DETECTION: FSM TESTING PLAN

Table #1a: Number of individuals planned to be tested, by month

BY MONTH:	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	TOTAL
Diagnostics*	26	200	400	400	500	500	400	400	2,826
Serology	0	0	0	0	200	400	500	500	1,600
TOTAL	26	200	400	400	700	900	900	900	

Table #1b: Planned expansion of testing jurisdiction-wide

Name of testing entity	Testing venue (select from drop down)	Performing Lab (if different from testing entity)	Daily diagnostic throughput	Daily serologic throughput	Platforms or devices used (list all)	Specific at-risk populations targeted (list all)
Pohnpei State Hospital	Public health lab	n/a	32	0		Health Care Works, Patient with co-morbidities (diabetes, COPD) Persons in very low socio-economic groups in multigenerational housing (gCommunity surveys have identified these households)
Chuuk State Hospital	Public health lab	n/a	32	0		Health Care Works, Patient with co-morbidities (diabetes, COPD) Persons in very low socio-economic groups in multigenerational housing (gCommunity surveys have identified these households)

ELC ENHANCING DETECTION: FSM TESTING PLAN

Name of testing entity	Testing venue (select from drop down)	Performing Lab (if different from testing entity)	Daily diagnostic throughput	Daily serologic throughput	Platforms or devices used (list all)	Specific at-risk populations targeted (list all)
Yap State Hospital	Public health lab	n/a	32	0		Health Care Works, Patient with co-morbidities (diabetes, COPD) Persons in very low socio-economic groups in multigenerational housing (gCommunity surveys have ideantified these households)
Kosrae State Hospital	Public health lab	n/a	32	0		Health Care Works, Patient with co-morbidities (diabetes, COPD) Persons in very low socio-economic groups in multigenerational housing (gCommunity surveys have ideantified these households)
Kolonia Community Health Centre	Community-based	Pohnpei State Lab	20	0		
Pohnlangas Dispensary	Community-based	Pohnpei State Lab	12	0		
Sokehs Dispensary	Community-based	Pohnpei State Lab	12	0		
Lukohp Dispensary	Community-based	Pohnpei State Lab	12	0		

ELC ENHANCING DETECTION: FSM TESTING PLAN

Name of testing entity	Testing venue (select from drop down)	Performing Lab (if different from testing entity)	Daily diagnostic throughput	Daily serologic throughput	Platforms or devices used (list all)	Specific at-risk populations targeted (list all)
Wone, Kitti Dispensary	Community-based	Pohnpei State Lab	12	0		
Tomil CHC	Community-based	Yap State Lab	12	0		
Gagil CHC	Community-based	Yap State Lab	12	0		
Maap CHC	Community-based	Yap State Lab	12	0		
Nimgill CHC	Community-based	Yap State Lab	12	0		
Colonia CHC	Community-based	Yap State Lab	20	0		
Weno, North CHC	Community-based	Chuuk State Lab	12	0		
Weno Central CHC	Community-based	Chuuk State Lab	12	0		
Weno South CHC	Community-based	Chuuk State Lab	12	0		

ELC ENHANCING DETECTION: FSM TESTING PLAN

Name of testing entity	Testing venue (select from drop down)	Performing Lab (if different from testing entity)	Daily diagnostic throughput	Daily serologic throughput	Platforms or devices used (list all)	Specific at-risk populations targeted (list all)
Tafunsak CHC	Community-based	Kosrae State Lab	12	0		
Utwe CHC	Community-based	Kosrae State Lab	12	0		
Malem CHC	Community-based	Kosrae State Lab	12	0		

ELC ENHANCING DETECTION: FSM TESTING PLAN

2020 Direct Expansion of SARS-COV-2 Testing by Health Departments

2. Describe your public health department's direct impact on testing expansion in your jurisdiction.

Expansion of Testing in the FSM: FSM plans to purchase additional modules for GeneXpert analyzers and also to purchase serology kits. FSM has been wait-listed for kits and analyzers. Additional laboratorians may be recruited for short-term contracts as required. At present, with no confirmed cases and border closure, there is no current need for additional laboratory personnel. Household surveys are being conducted to map vulnerable households: multi-generational housing, and housing with persons with diabetes, pulmonary disease or other co-morbidities. Persons in these households, and Healthcare workers and first responders have been identified as priority groups for testing. IT systems are being strengthened and more HCW placed at community centres to allow for decentralization of services and easier access to testing sites. Supply chain remains difficult, but the CDC/PIHOA/WHO collaboration has been able to fast track purchases for FSM and other island states. At present, given that FSM has no confirmed cases, and still has robust travel bans, serology testing is currently not indicated. FSM however plans to perform rapid serology testing using FDA approved Chembio kits. FSM also has strong relationships with Hawaii and Guam Public Health Laboratories for additional testing when indicated. FSM will continue to acquire kits based on estimated numbers in line with community mitigation strategies: numbers of vulnerable populations are being quantified, and numbers of incoming passengers have also been estimated.

ELC ENHANCING DETECTION: FSM TESTING PLAN

Table #2: Planned expansion of testing driven by public health departments

BY MONTH:	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	TOTAL
Number of additional* staff to meet planned testing levels	0	0	0	0	0	1	2	3	6
FOR DIAGNOSTIC TESTING									
How many additional* testing equipment/devices are needed to meet planned testing levels? (provide an estimated number, and include platform details in narrative above)	0	0	0	0	0	4	0	0	4
Volume of additional swabs needed to meet planned testing levels ⁺⁺	0	0	0	0	700	900	900	900	3,400
Volume of additional media (VTM, MTM, saline, etc.) needed to meet planned testing levels ⁺⁺	0	0	0	0	700	900	900	900	3,400
Volume of additional reagents needed to meet planned testing levels, by testing unit and platform (i.e. 100K/day - Hologic panther; 100k/day - Thermofisher)	0	0	0	0	0	900	900	900	2,700
FOR SEROLOGIC TESTING									
Number of additional* equipment and devices to meet planned testing levels	0	0	0	0	0	0	0	0	0

ELC ENHANCING DETECTION: FSM TESTING PLAN

BY MONTH:	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	TOTAL
Volume of additional reagents needed to meet planned testing levels, by testing unit and platform (i.e. 100K/day - Hologic panther; 100k/day - Thermofisher)	0	0	0	0	200	400	500	500	1,600

* Report new monthly additions only, not cumulative levels

++ For May and June, only include needs beyond the supplies provided by FEMA. Report new monthly additions only, not cumulative levels.